Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:23 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
NCT04480554 · University of Pennsylvania · PHASE2 · terminated · last registry update 2026-04-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Funding not renewed” | – | Registry record, University of Pennsylvania |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against OPRM1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Results posted on the registry: Henry M. Jackson Foundation for the Advancement of Military Medicine, Rifaximin 550 MG + Azithromycin 500 MG (NCT05677282)
- 2026-11-04Phase 3 first posted: National Institute of Allergy and Infectious Diseases (NIAID), naltrexone (NCT07916259)
- 2026-10-28Results posted on the registry: University of Alabama at Birmingham, a bundled intervention, including peer support specialist, buprenorphine, physician care, and telehealth (NCT06593093)
- 2026-10-22Results posted on the registry: University of California, San Diego, a drug against OPRM1 (NCT05872386)
- 2026-10-21Results posted on the registry: Mayo Clinic, Intravenous line (IV) Methadone + Intrathecal Morphine (NCT06826742)
- 2026-09-28Phase 3 first posted: The First Hospital of Jilin University, Tegileridine (tegileridine fumarate injection, IV) + Sufentanil (NCT07844512)
- 2026-09-23Results posted on the registry: Prisma Health-Upstate, a drug against OPRM1 (NCT06384781)
- 2026-09-08Phase 3 first posted: Region Skane, naloxone + Placebo (NCT07806565)
- 2026-09-08Also stopped (withdrawn): New York State Psychiatric Institute, Buprenorphine SL (NCT05339256)
- 2026-09-08Also stopped (terminated): Friends Research Institute, Inc., a drug against OPRM1 (NCT06569667)
- 2026-08-27Results posted on the registry: Frances R Levin, extended-release buprenorphine (BXR) + sublingual buprenorphine (BSL) (NCT04352166)
- 2026-08-26Results posted on the registry: Yale University, Naltrexone and Bupropion (NB) medication (NCT04605081)
- 2026-08-26Results posted on the registry: Yale University, Naltrexone and Bupropion medication (NCT04599478)
- 2026-08-20Results posted on the registry: Butler Hospital, Electronic Cigarette + Nicotine Lozenge (NCT05206435)
- 2026-08-19Results posted on the registry: Virginia Commonwealth University, Placebo + Auvelity (NCT05976646)
- 2026-08-17Also stopped (withdrawn): Wake Forest University Health Sciences, Single dose of methadone + Split dose of methadone (NCT07226245)
- 2026-08-13Results posted on the registry: University of Texas Southwestern Medical Center, a drug against OPRM1 (NCT05259501)
- 2026-08-06Results posted on the registry: Mayo Clinic, Oral methadone, immediately prior to transport + Intravenous methadone (NCT06720415)
- 2026-08-03Results posted on the registry: University of Michigan, a drug against OPRM1 (NCT04550715)
- 2026-07-31Also stopped (terminated): Boehringer Ingelheim, BI 1356225 + Placebo (NCT06628622)
- 2026-07-29Also stopped (terminated): Leiden University Medical Center, Narcan 40 MG/ML Nasal Spray + Naloxone Hydrochloride (NCT05338632)
- 2026-07-28Also stopped (withdrawn): Icahn School of Medicine at Mount Sinai, Clonazepam + Olanzapine (NCT06133114)
- 2026-07-17Results posted on the registry: University of Dundee, a drug against OPRM1 (NCT03935906)
- 2026-07-10Results posted on the registry: Stanford University, Naltrexone + Placebo (NCT04450316)
- 2026-07-10Also stopped (terminated): Stanford University, Naltrexone + Placebo (NCT04450316)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision